Home › Open-Angle Glaucoma › NCT06953349

Efficacy of Surgical Systems in Combination With Phacoemulsification: a Retrospective Analysis

Real-World Efficacy of Hydrus Microstent With OMNI Surgical System in Combination With Phacoemulsification: a Retrospective Analysis

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Subjects with h/o CEIOL/OMNI/Hydrus (chosen based on subjects on more than 1 medication pre-operatively) with at least 3 years of follow up data
* have Glaucoma

Exclusion Criteria:

* Patients with angle closure glaucoma or secondary forms of glaucoma due to neovascularization of the angle, uveitic glaucoma, congenital glaucoma, or glaucoma due to congenital anomalies.
* Patients with refractory CME or CME persisting 3 months or more post-operatively
* Patients with incomplete IOP, medication logs or VF data within post-operative period
* Prior incisional surgery or MIGS

About the study

Real-World efficacy of Hydrus Microstent with OMNI Surgical System in combination with Phacoemulsification: a retrospective analysis

What is being tested

• Real-World efficacy of Hydrus Microstent with OMNI Surgical System in combination with Phacoemulsification: a retrospective analysis (procedure)

Sponsor: Barnet Dulaney Perkins Eye Centers · Participants: 300 · Started: Mar 31, 2025

Contact the study team

• Derek J Arnson, Master of Education · Phone: 4804201005
• Christine Funke, Medical Doctor · Phone: 4804201005

Official record on ClinicalTrials.gov — NCT06953349

Locations in the U.S.

Conditions

• Open-Angle Glaucoma

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.